TXMD News and Press, TherapeuticsMD Inc. From 11/14/22

Therapeutics MD press release ( NASDAQ: TXMD ): Q3 GAAP EPS of -$3.13 misses by $1.09 . Revenue of $20.92M (-17.7% Y/Y) misses by $9.28M . As of September 30, 2022, the Company’s cash on hand totaled $27.1 million, compared with $65.1 million as of Decem...

- Q3 total revenue of $20.9 million - - ANNOVERA TRx growth of 10% year-over-year - - Reduced operating expenses by $22 million year-over-year - TherapeuticsMD, Inc. (“TXMD” or the “Company”) (NASDAQ: TXMD), an innovative, leading women’s h...

Summary Today, we put GoodRx Holdings in the spotlight for the first time.  This healthcare concern has destroyed much shareholder value over the past year. However, the company has recently resolved a major dispute and announced a significant restructuring that will reduce i...

TherapeuticsMD ( NASDAQ: TXMD ) has received an additional $7M private investment in the company’s Series A Preferred Stock from Rubric Capital Management. The additional funds will be used for working capital. Under the terms of the company’s financing a...

Maturity Date of Financing Agreement Extended to November 30, 2022 TherapeuticsMD, Inc. (NASDAQ: TXMD), (“TherapeuticsMD” or the “Company”) an innovative, leading women’s healthcare company, announced today that it received an additional $7...

TherapeuticsMD ( NASDAQ: TXMD ) has received a $7M private investment in the Company’s Series A Preferred Stock from Rubric Capital Management LP. TherapeuticsMD expects to use the proceeds from the transaction for working capital. Under the terms of the Company...

Maturity Date of Financing Agreement Extended to October 31, 2022, with the Ability to Extend to November 30, 2022, if Additional Capital is Raised TherapeuticsMD, Inc. (NASDAQ: TXMD), (“TherapeuticsMD” or the “Company”) an innovative, leading wom...

TherapeuticsMD ( NASDAQ: TXMD ) appointed Brian Bernick and Mark Glickman as interim co-CEO and co-principal executive officers. Bernick and Glickman succeed Hugh O’Dowd as CEO, the company said in a Sept. 12 press release. Prior to this appointment, Be...

- Robust Strategic Alternatives Process Continues - TherapeuticsMD, Inc. (NASDAQ: TXMD), (“TherapeuticsMD” or the “Company”) an innovative, leading women’s healthcare company, announced today the appointment of Dr. Brian Bernick and Mr. Mark Gl...

TherapeuticsMD's birth control ring saw year-over-year growth of almost 100% in Q2. Although costs came down significantly, TXMD continued to report an operating loss. Management believes a resolution to its recent inventory headwinds along with government support will drive incre...